Eris Lifesciences Dividends and Buybacks
Dividend criteria checks 3/6
Eris Lifesciences is a dividend paying company with a current yield of 0.46% that is well covered by earnings.
Key information
0.5%
Dividend yield
-0.03%
Buyback Yield
| Total Shareholder Yield | 0.4% |
| Future Dividend Yield | 0.6% |
| Dividend Growth | -3.5% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 28% |
Recent dividend and buyback updates
Recent updates
Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Nov 15
Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?
Aug 28Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Jul 26Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26%
Jun 17Eris Lifesciences' (NSE:ERIS) Conservative Accounting Might Explain Soft Earnings
May 26Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
May 23Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
Apr 28
Semaglutide Launch Will Secure Early Position In India's GLP-1 Market
Strategic GLP-1 market entry and Bhopal facility ramp-up are expected to boost revenue and margins through innovation and operational efficiency.These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Reasonably Well
Mar 03Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results
Feb 09What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E
Jan 07Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Stability and Growth of Payments
Fetching dividends data
Stable Dividend: ERIS has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: ERIS's dividend payments have increased, but the company has only paid a dividend for 6 years.
Dividend Yield vs Market
| Eris Lifesciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ERIS) | 0.5% |
| Market Bottom 25% (IN) | 0.3% |
| Market Top 25% (IN) | 1.3% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (ERIS) (up to 3 years) | 0.6% |
Notable Dividend: ERIS's dividend (0.46%) is higher than the bottom 25% of dividend payers in the Indian market (0.28%).
High Dividend: ERIS's dividend (0.46%) is low compared to the top 25% of dividend payers in the Indian market (1.32%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (28.4%), ERIS's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (16.6%), ERIS's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/30 05:55 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eris Lifesciences Limited is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Ashwin Mehta | Ambit Capital |
| Pranav Chawla | Ambit Capital |